MINORU TAKATA

Dr. MINORU TAKATA


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2011 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
JLJ Lin
J Lin
YGY Goto
Y Goto
HMH Murata
H Murata
KSK Sakaizawa
K Sakaizawa
AUA Uchiyama
A Uchiyama
MTMINORU TAKATA
MINORU TAKATA
Oncogenic BRAF mutation had been considered to be a founder event in the formation of melanocytic tumours; however, we recently argued against this notion by showing marked polyclonality of BRAF mutations in acquired melanocytic nevi (Lin et al, J Natl Cancer Inst., 2009; 101:1423–7). Here, we tested whether similar heterogeneity of BRAF mutations exists in primary melanomas. We isolated and sequenced single melanoma cells from five primary melanoma tissues using antibodies against human high-molecular-weight melanoma-associated antigen. We also examined 10 primary melanomas by the sensitive Mutector assay detecting the BRAFV600E mutation, as well as by cloning and sequencing of separated alleles. Furthermore, we estimated the frequency of BRAF mutant alleles in paired samples of primary tumour and recurrence or metastasis in three patients. Single-cell mutation analyses revealed that four of five primary melanomas contained both BRAF-wild-type and BRAF-mutant tumour cells. Tumour heterogeneity in terms of BRAF mutations was also shown in 8 of 10 primary melanomas. Selection of BRAF mutant alleles during progression was demonstrated in all the three patients. Acquisition of a BRAF mutation is not a founder event, but may be one of the multiple clonal events in melanoma development, which is selected for during the progression.

Verified
Journal Article
Open access
PDF file
Kazumasa WakamatsuKazumasa Wakamatsu
Kazumasa Wakamatsu
SFSatoshi Fukushima
Satoshi Fukushima
AMAkane Minagawa
Akane Minagawa
TOToshikazu Omodaka
Toshikazu Omodaka
THTokimasa Hida
Tokimasa Hida
HIHironobu Ihn
Hironobu Ihn
Melanoma is one of the most lethal and malignant cancers and its incidence is increasing worldwide, and Japan is not an exception. Although there are numerous therapeutic options for melanoma, the prognosis is still poor once it has metastasized. The main concern after removal of a primary melanoma is whether it has metastasized, and early detection of metastatic melanoma would be effective in improving the prognosis of patients. Thus, it is very important to identify reliable methods to detect metastases as early as possible. Although many prognostic biomarkers (mainly for metastases) of melanoma have been reported, there are very few effective for an early diagnosis. Serum and urinary biomarkers for melanoma diagnosis have especially received great interest because of the relative ease of sample collection and handling. Several serum and urinary biomarkers appear to have significant potential both as prognostic indicators and as targets for future therapeutic methods, but still there are no efficient serum and urinary biomarkers for early detection, accurate diagnosis and prognosis, efficient monitoring of the disease and reliable prediction of survival and recurrence. Levels of 5-S-cysteinyldopa (5SCD) in the serum or urine as biomarkers of melanoma have been found to be significantly elevated earlier and to reflect melanoma progression better than physical examinations, laboratory tests and imaging techniques, such as scintigraphy and echography. With recent developments in the treatment of melanoma, studies reporting combinations of 5SCD levels and new applications for the treatment of melanoma are gradually increasing. This review summarizes the usefulness of 5SCD, the most widely used and well-known melanoma marker in the serum and urine, compares 5SCD and other useful markers, and finally its application to other fields.


1 January 2006 in Skin Cancer
Verified
Journal Article
Closed access
SYShigeki Yoneyama
Shigeki Yoneyama
TSTetsuya Shiota
Tetsuya Shiota
SFShinichi Fujisaka
Shinichi Fujisaka
MTMINORU TAKATA
MINORU TAKATA
TSToshiaki Saida
Toshiaki Saida
SMSueo Miyaki
Sueo Miyaki

1 January 2008 in Skin Cancer
Verified
Journal Article
Closed access
KKKenji Kido
Kenji Kido
KTKyoko Tsuruta
Kyoko Tsuruta
HIHideyuki Ikegaki
Hideyuki Ikegaki
JSJunko Shiohara
Junko Shiohara
YKYukiko Kiniwa
Yukiko Kiniwa
SNShigeo Nakamura
Shigeo Nakamura

10 October 2008
Verified
Closed access
KSKaori Sakaizawa
Kaori Sakaizawa
JHJunichi Hasegawa
Junichi Hasegawa
SKShigeo Kawachi
Shigeo Kawachi
MTMINORU TAKATA
MINORU TAKATA
TSToshiaki Saida
Toshiaki Saida
SIShuichi Ikegawa
Shuichi Ikegawa